- Due to the variance seen in clinical samples, and the limited amount of material available from a single clinical sample, reproducible reference standards are required.
- Horizon’s Reference Standards are manufactured using cancer cell lines that have been engineered to contain or contain endogenously relevant biomarkers at a range of allele frequency.
- Horizon offers families of reference standards in a variety of formats: cell-free DNA (cfDNA), genomic DNA (gDNA), and Formalin-Fixed Paraffin-Embedded (FFPE) material.
- OncoSpan – The complete tool for assay validation, verification and routine monitoring with 152 genes and 380+ variants, and allele frequencies ranging between 1% and 100%
- Quantitative multiplex – Relevant for routine monitoring, contains multiple SNPs and INDELs, and includes 11 ddPCR-validated mutations, at 0.8-24.5% allele frequency.
- Structural multiplex– For confidence to determine structural variants. Designed to challenge your workflow by providing validated CNVs, translocations, and large INDELs. The Structural Multiplex includes 9 ddPCR-validated mutations, with most of them centred at 5% allele frequency.
- Multiplex I – Perform more robust Limit of Detection (LOD) testing. Suitable for input pre-and post- extraction to analyze impact of the liquid biopsy pre-analytical pipeline.
- Horizon uses these cell lines to create gDNA, cfDNA, FFPE, or formalin-compromised DNA (fcDNA) that can be used as a sequencing control.
- Unparallelled selection of relevant biomarkers may be used to confirm LOD in your assay and assess sequencing performance.
Reference Standards (Horizon)
Horizon offers diagnostic reference standards to ensure NGS assays are performing at the highest level. We have found optimization and validation of NGS workflows improve when using cell line-derived reference standards that closely represent the patient sample. Our aim is to provide reliable, reproducible and affordable cell-line derived reference standards to help improve confidence in NGS patient results. Scientists use Horizon diagnostic reference standards to develop or validate diagnostic assays, or to routinely monitor their diagnostic assay, ensuring the NGS assay is working properly. No matter the assay or specific challenge a clinical testing facility faces, there is a need for commutable controls that is a close representation of real clinical samples. We believe that control should be reliable, consistently available and affordable.
Horizon Discovery Ltd.
Cambridge Research Park,
Waterbeach, Cambridge, CB25 9TL